BioSpace News Archive

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, has added another patent family to its molecular residual disease (MRD)-related IP portfolio, with priority to January 2013.

MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), today announces the signing of a strategic platform license (SPL) with LG Chem Ltd., a globally diversified chemical company established in petrochemical, advanced materials and bio-technology, aiming to create new value for its customers based on science.

The global Point-of-Care Molecular Diagnostics market size was valued at US$ 2.85 billion in 2021 and is projected to surpass around USD 4.5 billion by 2030, poised to grow at a CAGR of 15.6% during the forecast period 2022 to 2030.

According to Vision Research Reports, the global Radiology As A Service market size is expected to be worth around US$ 6.7 billion by 2030.

According to Vision Research Reports, the global Surgical Robots market size is expected to be worth around US$ 9.30 billion by 2030.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) (“Bioceres” or the “Company”), a fully integrated provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, announced today the successful completion of its previously announced integration of Marrone Bio Innovations, Inc. (formerly NASDAQ: MBII) (“MBI”).

Baxter International Inc., a global medtech leader, announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock.

Assertio Holdings, Inc., a specialty pharmaceutical company offering differentiated products to patients, announced that effective July 1, 2022, the Compensation Committee of the Company’s Board of Directors granted four newly-hired employees a total of 17,772 restricted stock units and 18,553 stock options.

On the July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies.

The global Ceftriaxone Sodium market size is estimated to be worth US$ 264.2 million in 2021 and is forecast to a readjusted size of US$ 217.6 million by 2030 with a CAGR of -2.7% during the forecast period 2022-2030.